Autopsy report · NCT04444466

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

“internal company decision; not safety related”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

UCB Biopharma SRL

Sponsor type

Industry

Conditions

Healthy Study Participants; Chronic Spontaneous Urticaria

Interventions

UCB8600; Placebo

Participants

40

Sites

1

Countries

Bulgaria

Trials that died the same way

• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (97% match in meaning)
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
  “Company decision (not a safety issue)” (81% match in meaning)
• A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
  “Internal company decision” (79% match in meaning)
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
  “An internal business decision, not based on safety or regulatory considerations.” (78% match in meaning)
• Clinical Performance Evaluation of the Hativ P30
  “Company's internal decision.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.